UCSF Fresno leading-edge study lends hope to emphysema patientsOctober 22, 2008Patients in the Valley with emphysema might soon be breathing a little easier thanks to a new airway bypass study called the Exhale Airways Stents for Emphysema (EASE) trial. The trial principal is Dr. Karl Van Gundy aided by investigators Drs. Michael Peterson, Jose Joseph, Timothy Evans and Kathryn Bilello - all pulmonologists at UCSF Fresno Medical Education Program. The study is a multi-center, international trial that is designed to evaluate the safety and effectiveness of this new and innovative procedure. There are only two other sites administering the trial in California besides UCSF Fresno - UC Davis Medical Center and Cedars-Sinai Medical Center in Los Angeles. A form of chronic obstructive pulmonary disease (COPD), emphysema is a progressive lung disease that keeps air trapped inside the lungs (not allowing it to escape) resulting in shortness of breath. Since the disease develops gradually over many years, symptoms of emphysema might not occur until irreversible damage has already happened. "COPD is the fourth leading cause of death in the United States and a significant cause of disability in the world," said Dr. Peterson, who also is chief of medicine at UCSF Fresno Medical Education Program. "Very few new treatments have become available for this disease." The EASE trial procedure creates new pathways in the walls of the natural airways that connect the damaged inner lung tissue and the larger natural air passages. Dr. Peterson said these new passageways may provide a pathway for the trapped air in the inner lung to escape by "bypassing" the collapsing small airways. These new pathways are created using a special needle through a bronchoscope. After each new passage is made, a small drug-eluting stent (a wire mesh similar to what is used to keep coronary arteries open in heart disease) is implanted and provides support to keep the passageway open. Dr. Peterson said opening the airway allows the trapped air to escape the lungs, thereby hopefully relieving one of the symptoms of emphysema - shortness of breath. "A previous large trial (NETT) demonstrated that some patients with emphysema are helped by surgery to reduce the volume of air in the chest. However, this is a complicated and potentially dangerous surgical procedure. The EASE trial is designed to determine if a minimally-invasive approach to reducing lung volume could benefit patients with severe COPD," Dr. Peterson said. Both Drs. Peterson and Van Gundy are excited to offer this research approach soon to patients in the Central Valley. "We are currently enrolling patients in this trial and we will continue to enroll patients for next year," Dr. Van Gundy said. To find out more about the study you can go online www.easetrialus.com Broncus Technologies |
|||||||||||||||||||||
| Related Emphysema Current Events and Emphysema News Articles U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Survey: Awareness of COPD is rising, but understanding is still low Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. UT scientists discover link between protein and lung disease In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD). New genes at work in patients with hereditary lung disease University of Florida researchers have safely given new, functional genes to patients with a hereditary defect that can lead to fatal lung and liver diseases, according to clinical trial findings slated to appear this week in the online early edition of the Proceedings of the National Academy of Sciences. New genes at work in patients with hereditary lung disease Researchers at the University of Massachusetts Medical School and the University of Florida in Gainesville have safely given new, functional genes to patients with a hereditary defect that can lead to fatal lung and liver diseases. Scientists open doors to diagnosis of emphysema Chronic inflammatory lung diseases like chronic bronchitis and emphysema are a major global health problem, and the fourth leading cause of death and disability in developed countries, with smoking accounting for 90% of the risk for developing them. Emphysema severity directly linked to coal dust exposure Coal dust exposure is directly linked to severity of emphysema in smokers and nonsmokers alike, according to new research from the National Institute for Occupational Safety and Health (NIOSH). Lung volume reduction surgery shown to prolong and improve life for some emphysema patients Lung volume reduction surgery (LVRS) can have a significantly beneficial effect in patients with severe emphysema, according to the first ever study to randomize emphysema patients to receive either LVRS or non-surgical medical care. Protein may be strongest indicator of rare lung disease, study shows Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF). More Emphysema Current Events and Emphysema News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||